Group 1 for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Prostate Cancer+1 More
endorectal coi - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Multiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific antigen, which can decrease the rate of unnecessary biopsies and reduce the incidence of over-diagnosis of non-csPCa. Furthermore, there is evidence that MRI is more accurate in detecting high-grade (Gleason grade group ≥3) versus low grade cancers (Gleason grade group <2) and therefore may serve as a useful adjunct to prostate-specific antigen (PSA) testing, digital rectal examination, and prostatic biopsy to detect cancers that require definitive treatment as opposed to active surveillance. Many investigators, including our group, have shown the utility of preoperative mpMRI to assess the local extent of prostate cancer and for surgical planning.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year

Year 1
Malignant Neoplasms

Trial Safety

Trial Design

2 Treatment Groups

Group 1
1 of 2
Group 2
1 of 2

Experimental Treatment

258 Total Participants · 2 Treatment Groups

Primary Treatment: Group 1 · No Placebo Group · N/A

Group 1
Device
Experimental Group · 1 Intervention: flexible AIR coil · Intervention Types: Device
Group 2
Device
Experimental Group · 1 Intervention: endorectal coi · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,783 Previous Clinical Trials
1,784,646 Total Patients Enrolled
89 Trials studying Prostate Cancer
27,277 Patients Enrolled for Prostate Cancer
Tharakeswara BathalaPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
20 Total Patients Enrolled
1 Trials studying Prostate Cancer
20 Patients Enrolled for Prostate Cancer
Tharakeswara Bathala, MBBS,MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
2 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: November 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.